Net Worth Advisory Group acquired a new stake in Becton, Dickinson and Company (NYSE:BDX - Free Report) during the third quarter, according to its most recent filing with the SEC. The firm acquired 2,536 shares of the medical instruments supplier's stock, valued at approximately $611,000.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Stratos Wealth Advisors LLC raised its stake in Becton, Dickinson and Company by 9.8% during the 3rd quarter. Stratos Wealth Advisors LLC now owns 3,274 shares of the medical instruments supplier's stock worth $790,000 after buying an additional 291 shares during the period. Aspiriant LLC grew its position in shares of Becton, Dickinson and Company by 8.4% in the 3rd quarter. Aspiriant LLC now owns 1,171 shares of the medical instruments supplier's stock valued at $282,000 after purchasing an additional 91 shares during the period. Stonegate Investment Group LLC increased its stake in Becton, Dickinson and Company by 5.0% during the 3rd quarter. Stonegate Investment Group LLC now owns 5,536 shares of the medical instruments supplier's stock worth $1,335,000 after purchasing an additional 264 shares in the last quarter. Claro Advisors LLC raised its holdings in Becton, Dickinson and Company by 2,053.2% during the 3rd quarter. Claro Advisors LLC now owns 60,312 shares of the medical instruments supplier's stock worth $14,541,000 after buying an additional 57,511 shares during the period. Finally, Sumitomo Mitsui DS Asset Management Company Ltd boosted its holdings in shares of Becton, Dickinson and Company by 2.0% in the third quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 33,045 shares of the medical instruments supplier's stock valued at $7,967,000 after buying an additional 633 shares during the period. Institutional investors own 86.97% of the company's stock.
BDX has been the subject of several recent research reports. Raymond James reduced their price target on Becton, Dickinson and Company from $275.00 to $270.00 and set an "outperform" rating for the company in a research report on Friday, August 2nd. Citigroup upgraded shares of Becton, Dickinson and Company from a "neutral" rating to a "buy" rating and boosted their target price for the stock from $255.00 to $275.00 in a report on Tuesday, October 1st. StockNews.com raised shares of Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research report on Thursday, August 8th. Stifel Nicolaus upped their target price on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a "buy" rating in a report on Friday, July 26th. Finally, Evercore ISI lifted their price target on Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an "outperform" rating in a report on Tuesday, October 1st. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $282.63.
Read Our Latest Stock Report on Becton, Dickinson and Company
Shares of BDX stock opened at $243.75 on Friday. The stock has a market capitalization of $70.45 billion, a PE ratio of 53.69, a PEG ratio of 1.79 and a beta of 0.42. Becton, Dickinson and Company has a one year low of $218.75 and a one year high of $262.23. The business's 50 day simple moving average is $237.01 and its 200 day simple moving average is $235.24. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.85 and a quick ratio of 1.36.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share for the quarter, topping analysts' consensus estimates of $3.31 by $0.19. The firm had revenue of $4.99 billion during the quarter, compared to analyst estimates of $5.08 billion. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. The company's quarterly revenue was up 2.3% on a year-over-year basis. During the same quarter last year, the business earned $2.96 earnings per share. As a group, research analysts forecast that Becton, Dickinson and Company will post 13.11 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which was paid on Monday, September 30th. Stockholders of record on Monday, September 9th were paid a $0.95 dividend. The ex-dividend date of this dividend was Monday, September 9th. This represents a $3.80 dividend on an annualized basis and a dividend yield of 1.56%. Becton, Dickinson and Company's dividend payout ratio (DPR) is 83.70%.
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Becton, Dickinson and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.
While Becton, Dickinson and Company currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.